Skip to main content
. Author manuscript; available in PMC: 2012 Jun 4.
Published in final edited form as: Nat Biotechnol. 2011 Jun 19;29(7):635–643. doi: 10.1038/nbt.1899

Figure 3.

Figure 3

Kinetic analyses of known and putative biomarkers for acute myocardial infarction in PMI patients from discovery proteomics. (a) Known markers, such as CKM, MB, MPO and FABP showed little to no detection at baseline in coronary sinus plasma followed by a >5-fold increase at 10 min and 60 min after ablation in three PMI patients. (b) Eight potentially novel candidate biomarkers from discovery proteomics. These proteins showed no to little detection at baseline in coronary sinus plasma, then increased in MS abundance by at least fivefold at 10 min or 60 min after ablation in all three PMI patients. MRM-MS assays were configured for ACLP1, myosin light chain 3 and four-and-a-half LIM domain protein 1 to quantify these candidates in peripheral plasma of four PMI patients. Antibodies available for ACBP, ANG, MDK, malate dehydrogenase and ACLP1 were used either in ELISAs or western blot analyses to verify these candidates in additional patients (Supplementary Methods).